secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269535
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q3 revenue falls 13% YoY to $17.1M; lowers FY2025 revenue guidance to $70-74M
--------------------------------------------------------------------------------

- Net loss improved to $13.2M ($0.46 loss per share) from $16.2M in Q3 2024; cash use cut to $6.2M.
- Full-year 2025 revenue guidance lowered to $70-74M from prior $76-81M, citing MAC reimbursement headwinds.
- Sixth amendment to OrbiMed credit agreement adds $500K to principal, resets Q4 2025 revenue covenant to $70M.
- RECELL GO received CE Mark under EU MDR; launch to begin in Germany, Italy, and UK.
- Operating expenses down 24% YoY to $23.0M as part of cost discipline; cash $23.3M at Sept 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312525269535/0001193125-25-269535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312525269535/rcel-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer